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Abstract
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Megalencephaly-capillary malformation syndrome (MCAP) is an overgrowth disorder
characterized by cerebrocortical malformations, vascular anomalies, and segmental overgrowth
secondary to somatic activating mutations in the PI3K-AKT-MTOR pathway (PIK3CA). Cases of
growth failure and hypoglycemia have been reported in patients with MCAP, raising the suspicion
for unappreciated growth hormone (GH) deficiency. Here we report an observational multi-center
study of children with MCAP and GH deficiency. Eleven participants were confirmed to have GH
deficiency, all with very low or undetectable circulating concentrations of insulin-like growth
factor-1 and insulin-like growth factor binding protein-3. Seven underwent GH stimulation testing
and all had insufficient responses with a median GH peak of 3.7 ng/ml (range 1.1-8.6). Growth
patterns revealed a drastic decline in length z-scores within the first year of life but then stabilized
afterward. Five were treated with GH; one discontinued due to inconsolability. The other four
participants continued on GH with improvement in linear growth velocity. Other endocrinopathies
were identified in seven of the 11 participants in this cohort. This study indicates that GH
deficiency is associated with MCAP and that children with MCAP and hypoglycemia and/or
postnatal growth failure should be evaluated for GH deficiency and other endocrinopathies.

Keywords
MCAP; megalencephaly-capillary malformation syndrome; growth hormone deficiency;
hypoglycemia; PIK3CA
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The megalencephaly-capillary malformation syndrome (MCAP; OMIM#602501) is a
pediatric overgrowth disorder characterized by brain overgrowth (i.e. megalencephaly),
macrosomia, cutaneous vascular malformations, digital anomalies (polydactyly, syndactyly)
and cortical brain malformations (typically bilateral perisylvian polymicrogyria) (ClaytonSmith et al., 1997; Mirzaa et al., 2012; Moore et al., 1997). As an overgrowth disorder,
MCAP is characterized by several distinctive features that are typically recognizable at birth
including macrosomia, megalencephaly with or without overlying cortical malformations,
and cutaneous vascular malformations (Mirzaa, Riviere, & Dobyns, 2013). MCAP is most
commonly caused by mosaic (i.e., postzygotic) gain-of-function mutations in the PIK3CA
gene on the long arm of chromosome 3. These mutations lead to activation of the PI3KAKT-MTOR pathway, a critical cell-signaling pathway that regulates various cellular
functions including growth, proliferation, and metabolism (Cantley, 2002; Engelman,
Mukohara, et al., 2006; Mirzaa et al., 2013; Riviere et al., 2012).
While growth failure has not been reported as a key finding in classic MCAP, we have
identified a subset of children with MCAP and postnatal growth failure. Furthermore,
several children with this syndrome have been reported to have hypoglycemia, usually of
unknown etiology (Kinross et al., 2015; McDermott, Byers, & Clayton-Smith, 2016). Both
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postnatal growth failure and hypoglycemia can be presenting signs of GH deficiency, yet
there is only one published report to date of a child with MCAP and confirmed growth
hormone (GH) deficiency (Minagawa et al., 2005). This prompted us to launch this
observational study describing the phenotypes, growth trajectories, and endocrinological
manifestations of children with both MCAP and GH deficiency to facilitate early
identification and better management approaches for children with MCAP and
endocrinopathies.

METHODS

Author Manuscript

Participants were enrolled at one of two tertiary care referral centers under the appropriate
institutional research protocols. The first site is the Center for Integrative Brain Research
(CIBR) at the Seattle Children’s Research Institute (SCRI) that recruited nationally and
internationally for a study of megalencephaly and other developmental brain disorders. The
second site is the University of Colorado/Children’s Hospital Colorado that recruited
participants with MCAP and growth failure seen in the pediatric endocrinology clinic. To
avoid duplicate enrollment, initials and birth year were cross-compared between sites. One
participant was identified to have participated in studies at both sites, and data were
therefore merged for analysis. The local institutional review boards at both institutions
approved these studies with written informed consent provided from all enrolled families.
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Children with clinically and/or molecularly confirmed MCAP who also had confirmed GH
deficiency were included in this study. The diagnosis of MCAP was confirmed by clinical
geneticists, and when genetic testing results were available, by molecular diagnostic testing
(i.e., the identification of a disease-causing PIK3CA variant). Relevant data regarding
clinical phenotypes, comorbidities, and genetic findings were collected from medical
records. Growth parameters were obtained from clinical growth charts. To standardize
growth assessments, growth data were converted to age and sex-specific z-scores based on
the Fenton curves for birth parameters and Center for Disease Control (CDC) for postnatal
growth parameters (Fenton & Kim, 2013; Grummer-Strawn, Reinold, & Krebs, 2010).
Annual growth velocity was calculated by dividing the change in linear growth in
centimeters by the time between visits and normalizing it to 12 months. Due to expected age
differences in growth velocity, calculations were analyzed separately for age 0-1 years, 1-2
years, 2-4 years, 5-10 years, and 10+ years. Data on thyroid function, insulin-like growth
factor-1 (IGF-1), insulin-like factor binding protein-3 (IGFBP-3) concentrations, GH
response to hypoglycemia and/or stimulation tests, pituitary structure on brain magnetic
resonance imaging (MRI), and management of GH deficiency were collected, when
available. All laboratory data were measured clinically using different assays. Therefore, the
normal ranges for these assays vary and the data were not statistically compared. All records
were reviewed by a pediatric endocrinologist who confirmed the diagnosis of GH deficiency
(clinical symptoms plus laboratory criteria diagnostic of GH deficiency). Descriptive
statistics were used to summarize outcomes of interest using mean and standard deviation
unless otherwise specified.
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RESULTS
Eleven children had confirmed GH deficiency. The clinical characteristics of each
participant are presented in Table 1. All participants with GH deficiency who underwent
genetic testing (N=9) had a pathogenic variant in PIK3CA; for the other two, the diagnosis
of MCAP was made clinically but genetic testing was not pursued.

Author Manuscript

In our cohort, the mean gestational age was 36.0±1.4 weeks, mean birth weight z-score was
2.7±1.1 and mean birth length z-score was 2.3±0.8. Length or height z-scores from birth
through 5 years of age and growth velocities through 10 years of age are presented in Figure
1 and Figure 2, respectively. For most participants, there was a sharp decline in height zscores in the first year of life. After the first year of life, growth velocity remained stable and
in the low-normal range. However, there were individuals who did not follow this pattern
and seemed to grow normally until later in childhood. One participant (LR11-418) did not
have growth faltering at all and a diagnostic evaluation was only pursued due to anecdotal
knowledge of other cases of GH deficiency associated with MCAP (see Table 1 for
laboratory results).
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The mean age at the time of GH deficiency diagnosis was 4.2±3.0 years. At the time of
diagnosis, circulating IGF-1 and IGFBP-3 concentrations were low or undetectable in all
participants. Four underwent GH stimulation testing and/or had GH measured at the time of
hypoglycemia, and all had insufficient responses with mean peak GH concentration of 3.7
ng/ml (normal response >10 ng/ml). Of the 10 participants with brain MRIs, nine had
structurally normal pituitary glands and one had an incidental finding of a pars intermedia
cyst. Five participants (102, 105, LR11-230, LR12-037, and LR15-337) were treated with
subcutaneous recombinant human GH. Participant 102 discontinued GH after one week of
treatment due to symptoms of headache and inconsolability, although the etiology of his
irritability was not confirmed (more specifically, no papilledema or MRI changes were
noted). This child’s irritability resolved after discontinuing GH treatment. The other four
participants continued on GH with robust increases in linear growth velocity and no reported
side effects, including no clinical worsening of macrocephaly or hemihypertrophy. Five
(45%) participants with GH deficiency also had confirmed hypoglycemia. In four, the
occurrence of hypoglycemia preceded the diagnosis of GH deficiency. Notably,
hypoglycemia was attributed to several etiologies among these children, including
hypoglycemia secondary to GH deficiency (N=2), hyperinsulinism (N=1), and ketotic
hypoglycemia (N=2). Additional endocrine diagnoses observed in the participants with GH
deficiency included cryptorchidism (N=2), central hypothyroidism (N=1), central adrenal
insufficiency (N=1), antibody-positive type 1 diabetes (N=1), and osteoporosis with
pathologic fractures (N=1).

DISCUSSION
In this study, we describe the clinical presentation and management of 11 children with
MCAP and GH deficiency. Most participants presented with growth failure leading to a
diagnostic evaluation for GH deficiency. Four of the five participants treated with
recombinant human GH had an excellent response. This report of GH deficiency as well as
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other endocrinopathies, including hypoglycemia and other pituitary deficiencies, should
raise clinicians’ suspicion of these disorders in children with MCAP.
GH is secreted by the pituitary gland and has systemic effects, especially on bone and
muscle growth, as well as indirect effects through hepatic production of IGF-1 (De Luca,
2018). GH deficiency can result in poor linear growth, increased adiposity, decreased muscle
bulk, decreased bone mineralization, unfavorable lipid profiles, and occasionally fasting
hypoglycemia due to an inadequate counter-regulatory response (Chinoy & Murray, 2016).
While low IGF-1 is a sensitive but not specific screening test for GH deficiency, low
IGFBP-3 is recognized as the more specific but less sensitive biomarker of GH deficiency
(Trivin et al., 2006). One of the unique features found in this cohort of children with MCAP
is the universally low IGFBP-3 concentrations. Whether this is reflective of the severity of
GH deficiency or due to a unique mechanism in MCAP is unknown.
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We also suspect that postnatal growth retardation may be more common than previously
appreciated in MCAP. In one of the first papers describing 13 children with MCAP,
macrosomia at birth was nearly universal (Moore et al., 1997). However, at the time of
follow up, seven of these individuals had lengths <10th%ile and all but one had a decrease in
their length percentile from birth to the most recent follow up. The first published case of
MCAP and GH deficiency demonstrated postnatal growth retardation and developed
hypoglycemic seizures at seven months of age (Minagawa et al., 2005). His IGF-1
concentration was very low, and he had a low GH (1.1 ng/ml) at the time of hypoglycemia.
However, the patient had a normal response to GH releasing hormone (GHRH) stimulation
testing with a peak GH of 21 ng/dl. The management and clinical course of this patient were
not further described. Another report of a child with MCAP (megalencephaly,
polymicrogyria, hydrocephalus requiring shunt, and a mosaic gain-of-function mutation
p.Met1043Ile found in 16% in blood and 37% in saliva) also may have had GH deficiency.
He had hypoglycemia and low GH, IGF-1, and IGFBP-3 but there was no mention of
growth; he was briefly treated with GH but this did not resolve the hypoglycemia and he was
not given a diagnosis of GH deficiency (Stutterd et al., 2018). Finally, another child with
megalencephaly due to a germline mutation in AKT3 (p.Glu40Lys) has also been reported to
have GH deficiency and hypoglycemia. He was treated with recombinant GH around 15
months of age and hypoglycemia resolved. He did not have polymicrogyria, seizures, or
developmental delays (Takagi et al., 2017). This large case series substantially adds to the
literature describing GH deficiency among children with MCAP with PIK3CA mutations.

Author Manuscript

The underlying mechanisms of GH deficiency in MCAP are not well-understood. Classic
childhood GH deficiency has been attributed to inadequate GH production by the anterior
pituitary due to genetic mutations involved in pituitary gland development or signaling,
tumors, or brain malformations (especially optic nerve hypoplasia sequence) (Chinoy &
Murray, 2016). Given that a few of the children in our series had multiple pituitary hormone
deficiencies, congenital or acquired pituitary dysfunction is a potential etiology of GH
deficiency in MCAP as well. While the pituitary glands in our participants appeared
structurally normal on MRI, this does not exclude anterior pituitary dysfunction.
Furthermore, hydrocephalus is a known feature of MCAP and was present in 73% of our
cohort, and hydrocephalus has been associated with anterior pituitary deficiencies including
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GH deficiency (Cholley et al., 2001; Mirzaa et al., 2012; Moin, Bergsneider, Vespa, &
Heaney, 2012).
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The normal physiologic role of the PI3K-AKT pathway in downstream signaling for the
IGF-1, insulin and to a lesser extent, GH receptors, suggests alternative possible mechanisms
for the findings in our patients (Grimberg & DiMeglio, 2018). Gain-of-function mutations in
PIK3CA may mimic over- or constitutive activity of these 3 hormone receptors and
depending on the location of the post-zygotic mutations in patients with MCAP, determine
the pathophysiologic mechanisms and clinical features involved. If such gain-of-function
mutations occur centrally, they can mimic increased negative feedback on the hypothalamus
and pituitary, leading to reduced GH production and secretion. If the PIK3CA mutation is
not present in hypothalamic or pituitary tissues, individuals would be expected to have
normal GH releasing hormone (GHRH) and GH production and not exhibit symptoms of
GH deficiency. If instead the post-zygotic gain-of-function mutation occurs in target tissues,
direct negative feedback may inhibit growth factors through any number of known or
unknown regulatory feedback loops (Engelman, Luo, & Cantley, 2006). With GH and IGF-1
production downregulated, tissues that do not harbor the PIK3CA gain-of-function mutation
would not have this pathway activated, leading to symptoms of GH deficiency including
poor linear growth and hypoglycemia. Therefore, knowing which tissues the PIK3CA
mutation is present in would determine the phenotype. Finally, augmented clearance of GH,
IGF-1 and IGFBP-3 could be a mechanism of these low serum concentrations found in our
cohort. Given the complexity of the interactions that the PI3K-AKT-MTOR pathway has in
various tissues, further investigation of the underlying molecular mechanisms leading to GH
deficiency in MCAP are needed.
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The management of GH deficiency in MCAP is particularly challenging. Treatment of GH
deficiency in several reported cases appeared to improve hypoglycemia and normalize linear
growth velocity. However, it potentially could lead to worsened asymmetric overgrowth in
tissues with the activating PIK3CA mutation, particularly the brain. Although our sample
size is small, four of five children treated with GH had a positive response with no apparent
side effects, however one participant developed irritability and a concern for possible
intracranial hypertension, a known side effect of GH treatment. An additional consideration
with GH therapy is the theoretical concern for tumorigenesis. According to Pediatric
Endocrine Society, while data are insufficient to suggest that GH causes tumorigenesis,
children on GH treatment should be monitored closely if they have an increase risk of cancer
(Allen et al., 2016; Grimberg & Allen, 2017; Raman et al., 2015). Unlike several other
overgrowth syndromes, the risk of tumorigenesis in MCAP does not appear to be
significantly elevated (Mirzaa, Conway, Graham, & Dobyns, 1993; Swerdlow et al., 2017).
Overall, given the risk for death and neurodevelopmental issues with untreated
hypoglycemia that can be associated with GH deficiency, we recommend treatment with
conservative doses of GH in children with MCAP confirmed to have GH deficiency and
hypoglycemia. In the absence of hypoglycemia, the risks and benefits of management are
less clear and need to be evaluated on an individual basis. As there is little urgency to treat
for the purpose of increasing linear growth, waiting until after a child is two years of age
when the most rapid period of brain growth has ended is reasonable. Additional longitudinal
studies are needed to better delineate the safety and efficacy of GH in this context.
Am J Med Genet A. Author manuscript; available in PMC 2021 January 01.
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This study had several limitations. First, this is an observational study based on clinical data,
therefore, not all relevant data were uniformly available for review. Furthermore, detailed
endocrine data were specifically collected from those children with suspected or confirmed
endocrine dysfunction. Therefore, the prevalence of GH deficiency and other
endocrinopathies in all individuals with MCAP is difficult to determine with certainty, due to
ascertainment bias of this cohort. Finally, although it would be useful to fully understand the
mechanisms underlying GH deficiency in MCAP to enable an optimal therapeutic approach,
the role of PIK3CA mutations in various tissues to cause GH deficiency is currently unclear,
as mentioned above.

Author Manuscript

In summary, we report a series of children with MCAP and GH deficiency, suggesting that
GH deficiency is an underappreciated and clinically relevant feature of this megalencephaly
overgrowth disorder. Therefore, we recommend that children with MCAP and either
hypoglycemia and/or postnatal growth failure be evaluated for GH deficiency and treatment
considered on a case-by-case basis. This study includes a large sample size for this rare
genetic syndrome, however additional research is needed to accurately determine the overall
prevalence, mechanisms, and best management for GH deficiency in children with MCAP.
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Figure 1. Growth trajectory (length or height z-scores) from birth to five years for each
participant with MCAP and confirmed GH deficiency.

Dotted lines for participants 105 (purple diamond) and LR11-230 (pink circle) indicate
growth trajectory following the initiation of GH treatment.
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Figure 2. Growth velocity from birth to ten years of age for participants with MCAP and
confirmed GH deficiency.

Normal growth velocity is shown in grey. Growth velocity is notably lower in the first year
of life.
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Figure 3. Possible mechanisms for growth hormone (GH) deficiency in children with mosaic
gain-of-function mutations in the PI3K-AKT-MTOR pathway:

1) Hypopituitarism associated with other central nervous system abnormalities (classic GH
deficiency); 2) negative inhibition of GHRH from the IGF-1R signaling pathway being
constitutively activated at the level of the hypothalamus; 3) negative feedback from cell
growth signaling products of the constituently active PI3K pathway in target cells; and 4)
increased clearance of growth factors. GHRH = growth hormone releasing hormone; GH =
growth hormone; IGF-1 = insulin-like growth factor 1; R=receptor; IGFBP-3 = insulin-like
binding protein 3
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Summary of the clinical and genetic data of patients with MCAP and confirmed GH deficiency (N=11).

Birth
length
(cm, z‡
score )

Age at
diagnosis
of GH
deficiency
(yrs)

Fre
T4
(ng/
L)
Ref
0.8-2
ng/d

Author Manuscript
Author Manuscript

Phenotype

Neurodevelopment

White/
Hispanic

H+, M,
CCM,
HEMI

Moderate delays

4.6, 3.2

54.0,
2.6

0.8

<25
(55-327)

0.6
(0.7-3.6)

7.3

1.2

M

White/
Caucasian

H-, M,
CCM, PM,
DA, ChM

Mild delays

3.6, 2.7

-

7.4

49
(18-307)

1.8
(1.8-5.0)

5.3

-

p.Glu726Lys

M

White

H+, M,
DA

Severe delays,
seizures

3.8, 3.1

-

4

32
(49-351)

0.8
(1.8-7.1)

1.1

1.0

LR11-230

p.Gly1049Ser

M

Unknown

H+, M,
DA

Moderate delays

4.0, 3.0

54.5,
3.1

3.7

24
(30-155)

0.8
(0.9-4.3)

8.6

-

102

p.Gly914Arg

M

White

§

Moderate delays,
seizures

2.5, 0.5

49.5,
1.9

0.6

<10
(30-22)

<0.5
(0.7-3.6)

-

0.8

LR15-337

p.Gly914Arg

M

White/
Caucasian

M, HEMI,
ChM

Moderate delays

3.4, 1.7

49.0,
0.8

2.2

16
(18-176)

N/A

3.4

-

105

p.Met1043Ile

F

White

H+, M,
CCM

Moderate delays

3.0, 0.3

53.3,
2.3

1.8

<25
(55-327)

0.6
(0.7-3.6)

2.5

0.8

LR14-100

p.Met1043Ile

M

White/
Caucasian

M, CCM,
DA, PM

Severe delays

4.0, 3.7

52.7,
2.8

-

<10
(16-233)

<0.5
(1.8-5.0)

-

-

LR18-218

p.Met1043Ile

M

White/
Ashkenazi
Jewish

M, PM,
DA, CCM,
CA, HEMI

Moderate delays

4.8, 3.8

-

3.5

18
(49-283)

0.78
(1.6-4.6)

3.7

1.5

101

Not
performed

F

White/
Hispanic

H+, M,
CCM

Mild delays

4.4, 2.1

53.5,
1.7

3.8

<25
(49-283)

<0.5
(0.8-0.3)

-

-

104

Not
performed

F

White

H+, M,
CCM

Profound delays,
seizures

4.2, 3.2

52.7,
2.4

¶

<25
(88-452)

<0.5
(1.8-7.1)

-

1.1

ID

PIK3CA
variant

Sex

103

p.Asn345Ile

F

LR11-418

p.Cys378Tyr

LR12-037

Race/
Ethnicity

H- , M,
CCM

†

9.2

IGF-1
(ng/mL,
normal
range)

IGFBP-3
(mg/L,
normal
range)

Abbreviations: M = megalencephaly; H+ = hydrocephalus with shunt; H− = hydrocephalus without a shunt; CCM = cutaneous capillary
malformation; PM = polymicrogyria; DA = digit abnormalities (syndactyly or polydactyly); CA = cardiac arrhythmia; HEMI = hemihypertrophy;
ChM = Chiari malformation.

†

Based on clinical review.

‡

Based on Fenton growth charts.

§

Participant underwent a ventriculostomy.

¶

GH
stimulation
maximum
peak
(ng/mL)

Birth
weight
(kg, z‡
score )

Growth failure occurred by age 6 but was not evaluated due to more significant health concerns.
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